It was an absolute pleasure to talk with Jeffrey Curtis (University of Alabama at Birmingham, Birmingham, AL, USA) to discuss whether patients could maintain rheumatoid arthritis remission on monotherapy after discontinuing either methotrexate or etanercept (Clinical Trial Identifier: NCT02373813).
The abstract entitled ‘Maintenance of Remission After Withdrawal of Etanercept or Methotrexate in Patients with Rheumatoid Arthritis in Sustained Remission on Combination Therapy: Results from a Randomized, Double-blind, Controlled Trial’ (ABSTRACT NUMBER: 0939) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- What are the challenges facing patients in remission on combination therapy of methotrexate plus etanercept? (0:14)
- What is the rationale for discontinuing one of these medications and continuing with monotherapy? (1:47)
- Could you tell us a little about your study, its findings and the implications for clinical practice? (4:42)
- How can remission be regained if it is lost following withdrawal of methotrexate? (6:35)
Disclosure: Consulting fees and research grants to the university from Amgen
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Rheumatoid Arthritis
Kevin Winthrop, ACR 2022: Integrated safety analysis of filgotinib in moderately to severely active rheumatoid arthritis
Filgotinib, is an oral Janus kinase 1 inhibitor approved in Europe, Japan, and the UK for the treatment of patients with moderately to severely active rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to discuss the objectives, methodology and findings from […]
Paul Studenic, ACR 2022: A validation study of the revised ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the methodology and findings of the validation […]
Paul Studenic, ACR 2022: The 2022 revision of the ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis (RA) over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the limitations of the Boolean and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!